Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma

STATUS

Recruiting
End date

Apr 24, 2023
participants needed

100
sponsor

Asan Medical Center

Send

Updated on 24 February 2022

See if I qualify

malignant disease

renal function

cancer

absolute neutrophil count

carcinoma

treatment regimen

kidney function tests

metastasis

neutrophil count

capecitabine

gemcitabine

chemotherapy regimen

adjuvant chemotherapy

cholangiocarcinoma

extrahepatic cholangiocarcinoma

serum total bilirubin

Summary

There is no proven adjuvant treatment after curative surgical resection in patients with cholangiocarcinoma, although previous meta-analysis suggested potential survival benefit of adjuvant chemotherapy or radiotherapy in patients with lymph node-positive resected cholangiocarcinoma. Despite of lack of level 1 evidence and no data which regimen is optimal, adjuvant chemotherapy is widely used in daily practice setting. Based on this background, the investigators designed the randomized phase 2 trial comparing capecitabine and gemcitabine plus cisplatin in patients with resected lymph node-positive extrahepatic cholangiocarcinoma.

Details

Condition	Cholangiocarcinoma, Biliary Tract Cancer, Adjuvant Chemotherapy, Capecitabine, Gemcitabine, Cisplatin
Treatment	Capecitabine, Gemcitabine plus cisplatin
Clinical Study Identifier	NCT03079427
Sponsor	Asan Medical Center
Last Modified on	24 February 2022

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Patients aged 19 years and older
	Histologically documented extrahepatic cholangiocarcinoma (perihilar or distal bile duct tumor)
	Microscopic or macroscopic surgical resection (ie., R0 or R1 resection)
	Regional lymph node metastasis according to the American Joint Committee on Cancer (AJCC) 7th edition
	No distant metastasis
	Eastern Cooperative Oncology Group (ECOG) performance status 0 ~ 1
	No prior chemotherapy or radiotherapy
	Serum CA 19-9 < 100 U/mL at the time of enrollment
	Adequate bone marrow function as defined by platelets 100 x 109/L and neutrophils 1.5 x 109/L
	Adequate renal function, with serum creatinine < 1.5 x upper limit of normal (ULN)
	Adequate hepatic function with serum total bilirubin < 2 mg/dL, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 2.5 x ULN
	No other malignant disease apart from non-melanotic skin cancer or carcinoma in situ of the uterine cervix or any other non life-threatening cancer (i.e., prostate or thyroid cancer) except where treated with curative intent > 5 years previously without evidence of relapse Written informed consent to the study
Exclusion Criteria
	Medical or psychiatric conditions that compromise the patient's ability to give informed consent or to complete the protocol or a history of non-compliance
	Histologies other than adenocarcinoma such as mixed hepatocellular carcinoma/cholangiocarcinoma, adenosquamous carcinoma or mixed adenocarcinoma/neuroendocrine carcinoma
	Intrahepatic cholangiocarcinoma or gallbladder cancer
	Obstruction of gastrointestinal tract
	Active gastrointestinal bleeding
	Myocardial infarction within 6 months prior to the study medication, and other clinically significant heart disease (e.g., unstable angina, congestive heart failure or uncontrolled hypertension)
	Evidence of severe or uncontrolled systemic disease or any concurrent condition which in the investigator's opinion makes it undesirable for the patient to participate in the study or which would jeopardise compliance with the protocol
	Female subjects who are pregnant or lactating, or males and females of reproductive potential not willing or not able to employ a highly effective method of birth control/contraception to prevent pregnancy from 2 weeks before receiving study drug until 3 months after receiving the last dose of study drug. A highly effective method of contraception is defined as having a low failure rate (< 1% per year) when used consistently and correctly

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

0/250

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

malignant disease

renal function

cancer

absolute neutrophil count

carcinoma

treatment regimen

kidney function tests

adjuvant chemotherapy

cholangiocarcinoma

extrahepatic cholangiocarcinoma

serum total bilirubin

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma